GILD · 8-K · 20260804PR000028
Geographic Market Commentary
GILEAD SCIENCES, INC. · 2026-08-04 · Importance 57 · Surprise 38
Second-quarter product sales totaled $5.6 billion in the U.S., $1.2 billion in Europe and $872 million in the Rest of World. U.S. HIV sales were $4.7 billion, including $3.0 billion of Biktarvy and $921 million of Descovy. Europe generated $1.2 billion of product sales, while Rest of World contributed $872 million. The strongest geographic product expansion was in U.S. Descovy, which increased from $601 million to $921 million, and U.S. Livdelzi, which increased from $74 million to $147 million.